

# CUMULATIVE INDEX 1993

## Volume 11

---

March	NUTRITION IN THE INTENSIVE CARE UNIT, pages 1-103
	GASTROENTEROLOGY, pages 105-219
June	CRITICAL CARE PHARMACOLOGY, pages 221-387
September	COAGULOPATHY AND HEMATOLOGY, pages 389-568
December	MANAGEMENT OF CHRONIC HEART FAILURE, pages 569-672
	THORACIC TRAUMA, pages 673-773

---

Note: Page numbers of article titles are in **boldface** type

- Abbokinase. See *Urokinase (Abbokinase)*.
- ABC. See *Airway, breathing, circulation (ABC)*.
- Abruptio placentae, 482-483
- Absorption, drug, in adults, 229-231  
in children, 367-368
- Acetaminophen, 289, 291
- Acetazolamide, for chronic heart failure, 584
- Acid-base, in fulminant hepatic failure, 146
- ACLS (Advanced Cardiac Life Support) guidelines, 247
- Acute myocardial infarction (AMI), thrombolysis for,  
alteplase in, 364-365  
urokinase in, 360
- Adult respiratory distress syndrome (ARDS), after bone  
marrow transplantation, 538  
pathophysiology of, complement activation in, 725-  
727  
macrophages in, 729  
neutrophils in, 726  
oxygen metabolites in, reactive, 726-727  
pharmacotherapy for, 732  
post-traumatic, 723-734  
definition of, clinical, 725-727  
incidence of, 723-724  
respiratory therapy for, extracorporeal membrane oxy-  
genation/carbon dioxide removal in, 729-731  
inhaled nitric oxide, 731  
inverse ratio ventilation, 729-730  
standard, 728-729
- Advanced Cardiac Life Support (ACLS) Guidelines, 247
- Aerosol therapy, in intubated patients, charting of, 279  
complications of, 278  
devices for, 273-277  
limitations of, 274-277  
response to, objective, 277-278  
subjective, 278  
with mechanical ventilation, 271-280  
anti-infective, 271-272  
bronchodilators in, 272  
response to, 277-278  
indications for, 271  
nebulizer versus metered-dose inhaler for, 273-274
- Afibrinogenemia, 451
- AHG (antihemophilic globulin [AHG] deficiency). See  
*Hemophilia(s), factor VIII deficiency*.
- AIDS. See *HIV/AIDS*.
- Airway, breathing, circulation (ABC), in blunt chest  
trauma, 673-674  
in penetrating chest injury, 689-690
- Albumin, 8-9. See also *Prealbumin*.
- Alcohol, pancreatitis from, acute, 186
- Allopurinol, for inflammation and coagulopathies, 430
- Alteplase (recombinant tissue plasminogen activator  
[r-TPA]), dosage of, 364-365  
in acute myocardial infarction, 364-365  
in peripheral arterial occlusion, studies of, 362, 363  
reconstitution of, 365  
versus streptokinase and urokinase, 362, 364
- AMI. See *Acute myocardial infarction (AMI)*.
- Amidate. See *Etomidate (Amidate)*.
- Aminoglycosides, in pediatric patient, 373-374  
resistance to, 314-315
- Ammonia, encephalopathy from, hepatic, 42
- Amrinone, for chronic heart failure, 594  
for congestive heart failure, acute, 264-265
- Amylase, serum level, in pancreatitis, 189-190
- Analgesia, 281-295  
administration of, 289-290  
epidural, 292-293  
intramuscular, 290  
intrathecal, 292-293  
intravenous, continuous infusion, 292  
intermittent injection in, 290-292  
oral, 290  
patient-controlled, 292  
transdermal, 293  
transmucosal, 293  
adverse reactions to, 286-288  
anesthetic, local, 283-285, 289, 291  
dosage of, 289-291  
drug interactions in, 288-289  
epidural, in thoracic trauma, 717-718, 720  
postesophagogastrectomy, 181  
indications for, 283-284  
intrathecal, 718

Analgesia (*Continued*)

- mechanisms and site of action of, 282-283
- monopolizing of, 294
- nonopioid, 282-291
- opioid, 282-284, 289-291
- patient-controlled, 719
- pharmacokinetics of, 284-286
- Anastomosis, leakage from, postesophagegastrectomy, 182-183
  - posttransplantation, of small intestine, 210-211
- Anectine. *See Succinylcholine (Anectine).*
- Anesthesia, head injury and, 703
  - in thoracic trauma, 697-711
    - agents for, 704-706
    - airway management and ventilation in, 697-699
    - cervical spine management and, 701, 703
    - extubation and, 707-708
    - induction of, rapid sequence, 699-701
    - intraoperative management of, 703-707
    - intubation for, 697-699
    - local, for pain management, 719
    - neuromuscular blockade and, 706-707
    - pharmacology and, 703-704
    - postoperative management of, 707-709
- Anesthetic(s), fentanyl, for analgesia, 293
  - local, adverse reactions to, 288
    - dosage of, 291
    - drug interactions with, 289
  - in thoracic trauma, 719
  - indications for, 284
  - mechanism and sites of action of, 283
  - pharmacokinetics of, 285
- Angina pectoris, in atherosclerosis, 356
- Angiotensin-converting enzyme (ACE) inhibitors, actions of, 601-602
  - clinical uses of, 603-604
    - for chronic heart failure, 267, 584
  - patient outcomes and, 602-603
  - studies of, 602-603
- Anorectal disease, HIV/AIDS-related, 124-125
- Antacids, prophylactic, for stress ulceration, 167
- Anthropometric measurements, 4, 6-7, 99
- Antibiotic(s), 313-323
  - administration of, considerations in, 321-322
  - aminoglycoside, 314-315
  - beta-lactam, 315-318
  - broad-spectrum, vitamin K deficiency from, 456
  - for bacteremia, 320-321
  - for nosocomial infections, 313-314, 318-320
  - for urinary tract infections, 320
  - quinolone, 315
  - resistance to, bacterial, 313-314
- Anticoagulant(s)
  - heparin, 519-521
  - warfarin, 517-519
- Anticoagulation, for heart disease, 511
  - for pulmonary thrombosis, 494
- Anticonvulsant(s)
  - barbiturates, 239
  - benzodiazepines, 238
  - lidocaine as, 239
  - paraldehyde, 239
  - phenytoin, 238-239
  - valproate, 239
  - valproic acid, 239
- Antididotoxin therapy. *See also Immunotherapy; Shock, septic.*
  - HA-1A, pharmacy and therapeutics committee and, 380, 382
  - physician order for, 381
- in sepsis, 345-354
  - case studies of, 349-352
    - protocol for, 354
  - history of, 347-349
  - monoclonal, 336, 348-350
  - polyclonal antiserum, 347-348
- Antifibrinolytic agent(s), for coagulopathy, postoperative, 469-470
- Antihemophilic globulin (AHG) deficiency. *See Hemophilia(s), factor VIII deficiency.*
- Antioxidants, for inflammation and coagulopathies, 430
- Antithrombin III, activity of, 499-501
  - deficiency of, acquired, associated pathologies, 503-505
    - in pregnancy, 505-506
    - mechanisms of, 503
    - neonatal, 506
  - hereditary, 501-503
    - classification of, 501-502
    - diagnosis of, 502-503
    - manifestation of, 502
    - treatment of, 503
  - molecule, 499-500
- Antithrombin III (ATIII) concentrate, clinical studies of, 506-507
  - for disseminated intravascular coagulation, 406
  - with heparin, for thrombosis, 506-507
- Anti-TNF (antitumor necrosis factor), for septic shock, 238
- Antitumor necrosis factor (anti-TNF), for septic shock, 238
- Aorta, disruption of, complications of, 683-684
  - from blunt chest injuries, 682-684
  - mortality from, 682
  - repair of, 682-683
  - penetrating injury to, 691-693
  - transection of, mortality from, 691
  - thoracotomy for, 691-692
- Apoproteins, 436-437
- Aprotinin, for coagulopathy, postoperative, 469-470
- Arachidonic acid, metabolites of, in coagulation and inflammation, 418
- ARDS. *See Adult respiratory distress syndrome (ARDS).*
- Arginine, immune response and, modulation of, 115-117
  - in enteral nutrition, 26
  - in refeeding, in hypermetabolism, 102
- Arteriography, pulmonary, 492
- Atherosclerosis. *See also Thrombolysis.*
  - pathophysiology of, 355-356
- Atracurium, 302-303
- Atrial fibrillation, sudden cardiac death and, 611-612
- Atropine, in resuscitation, 254, 257-258
- Autonomy, patient, 19, 377
- Bacteria, commensal, 110
  - in gut, 110, 113
  - translocation of, 24-25, 113, 212
- Barbiturates, for intracranial pressure reduction, 242
  - for seizures, 239
  - in thoracic trauma, 706-707
- Beneficence, 19, 377
- Benzodiazepines, for seizures, 238
  - in thoracic trauma, 705-706, 709
- Beta-adrenergic agonists, for chronic heart failure, 591
  - in combination therapy, 592-593
  - long-term use of, 593-594
  - tolerance to, 592
- Beta blockers, for cerebral perfusion, 244

- for chronic heart failure, actions of, 604-605
  - classification of, 605
  - clinical use of, 606
  - patient outcomes with, 605-606
- for congestive heart failure, acute, 267
- for portal hypertension, 159
- Beta-lactam antibiotics, classification of, 317
  - examples of, 317
  - resistance to, 314-318
    - mechanisms in, 316-317
  - structures of, 316
  - trade names of, 318
- Biliary tract disease, HIV/AIDS-related, 124
- Bleeding, after bone marrow transplantation, 534-535
  - after implantation of ventricular assist devices, 656-657
  - after thrombolytic and anticoagulant therapy, 365, 511-523
    - See also *Thrombolysis; Anticoagulation.*
    - heparin-associated, 520
    - in hemophilia, 448-449
    - warfarin-associated, 517-519
- Blood, antigens in, in group and typing, 544
  - clotting factors in, 454-455
  - components of, 544-550
  - physiology of, 543-544
- Blood component replacement therapy, 543-556. See also *Transfusion.*
  - administration of, 554
  - assessment for, 552-553
  - components for, 544-550
  - evaluation of, 555
  - in disseminated intravascular coagulation, 405
  - monitoring of, 554-555
  - patient education for, 553
  - personnel coordination for, 553
  - procurement and identification for, 553-554
  - reactions to, 550-552
- Blood vessels, abnormalities of, congenital coagulopathies from, 445-446
- Blunt chest injury(ies), 673-686
  - assessment of, airway, breathing, circulation in, 673-674
    - fractures in, 674
    - laboratory, 675
    - radiologic, 675
  - cardiac output alterations in, 681
  - impaired gas exchange in, from pulmonary contusion, 678-679
  - ineffective airway in, from tracheobronchial tears, 679-681
  - pericardial tamponade in, 681
  - tension pneumothorax from, 679
  - types of, aortic disruption, 682-684
    - cardiac contusion, 681
    - fractures, 676-678
    - pulmonary contusion, 676-678
    - tracheobronchial tears, 679-681
  - ventilation alterations in, from bony thorax fractures, 675-676
    - from pleural space injuries, 678-679
- BMT. See *Bone marrow transplantation (BMT).* Bone marrow transplantation (BMT), 531-542
  - allogeneic, 532, 535
  - autologous, 532, 535
  - complications following, 533-541
    - cardiac, 538-539
    - early, 533-534
    - graft failure, 535
    - graft-versus-host disease, 535-538
    - hematologic/immunologic, 534-535
    - hepatic, 539-540
    - immediate, 533
    - multisystem organ disease, 540-541
    - neurologic, 540
    - renal, 539
    - respiratory, 536-538
  - history of, 531-532
  - indications for, 532
  - process in, 532-533
  - survival rates in, 533
  - syngeneic, 532
  - types of, 532
- BPD. See *Bronchopulmonary dysplasia (BPD).*
- Bradycardia, pharmacotherapy for, in resuscitation, 257-258
- Bretium, in resuscitation, 255, 257
- Bronchiolitis obliterans, after bone marrow transplantation, 538
- Bronchopulmonary dysplasia (BPD), nutritional support
  - in, in adults, 73-74
  - in children, 73-75
- Budd-Chiari syndrome, fulminant hepatic failure from, 143
- CABG. See *Coronary artery bypass grafting (CABG).*
- Calcium channel blockers, for cerebral perfusion, 244
  - for intracranial pressure reduction, 242
  - in congestive heart failure, acute, 267-268
- Calories, requirement for, 12
  - Harris-Benedict equation for, 12
  - resting-energy expenditure for, 12-13
- Calorimetry, in adult, direct, 12-14
  - indirect, 14
  - in child, direct, 67-68
  - indirect, 68
- Campylobacter*, diarrhea from, 122
- Cancer, esophageal, epidemiology and etiology of, 177
  - esophagostomy for, 178-183
  - presentation of, 177
- Candidiasis, oral, HIV/AIDS-related, 123-124
- Cannulation, arterial, catheter in, 558-559
  - complications of, 558
  - management of, 559-561
  - monitoring systems in, 559
  - Thunder Project study of, 557-560
- Captopril, for chronic heart failure, 603
- Carbapenems, resistance to, 317
  - structures of, 316
  - trade names of, 318
- Carbohydrates, in hypermetabolism, in refeeding, 101
  - metabolism of, 97-98
  - requirement for, in cardiopulmonary disease, 59-61
  - in children, 68, 73-75
- Carbonic anhydrase inhibitors, for chronic heart failure, 584
- Cardiac output, after cardiac transplantation, 639-641
  - in chest injury, 681
  - in inflammation and coagulopathies, 428-429
- Cardiac toxicity, after bone marrow transplantation, 538-539
- Cardiac transplantation, alternatives to, coronary artery bypass grafting, 624
  - outcomes of, 624-625
  - percutaneous transluminal coronary angioplasty, 623-624
  - in end-stage heart failure, 635-648
  - donor issues in, 635-637

- Cardiac transplantation (*Continued*)  
 organ availability, 635-636  
 selection criteria, 636  
 long-term considerations in, hypercholesterolemia, 646  
 hypertension, 645  
 infection, 643, 645  
 nutrition, 646  
 psychosocial outcomes, 646  
 renal insufficiency, 645-646  
 operative procedure in, 639  
 postoperative complications of, 639-640  
 post-transplant care and, 640-643  
 recipient issues in, 637-638  
 communication, 637-638  
 financial, 637  
 selection criteria, 637  
 rejection and, 641-643  
 immunosuppressive therapy for, 643-644  
 types of, 641-643  
 success of, 635  
 waiting period for, outcomes in, 638-639  
 survival following, 623, 635
- Cardiomyoplasty, dynamic, history of, 627-628  
 objectives of, 627, 630  
 outcome data for, 632  
 patient selection for, 620-621  
 postoperative complications of, 622  
 postoperative nursing and, 631-632  
 pulse train stimulation and, 629, 630  
 skeletal muscle transformation and, 628-629  
 for chronic heart failure, 627-633
- Cardiomyostimulation, in cardiomyoplasty, 629, 630
- Cardiopulmonary bypass, coagulopathies from, postoperative, 464
- Cardiopulmonary disease, bronchopulmonary dysplasia, 73-75  
 congenital heart defects, 74-76  
 malnutrition in, 57-59  
 nutritional support in, 57-64  
 complications from, 62  
 effectiveness of, 61-62  
 enteral, 61  
 nutrients in, 59-61  
 parenteral, 61  
 pediatric, 74-76
- Cardiopulmonary resuscitation (CPR), dopamine in, 252-253  
 epinephrine in, 250-253  
 norepinephrine in, 252-253  
 phenylephrine in, 252, 254  
 vasoactive drugs in, 250-252
- Cardiovascular disease, antithrombin III in, 504-505
- Cardiovascular function, treatment outcomes  
 management and, continuum of care and, 746  
 emergency department guidelines for, 749-750
- Cardiovascular system, anesthetic effects on, 704  
 in disseminated intravascular coagulation, 402  
 pediatric, anatomy and physiology of, 370-371  
 catecholamines and, 371  
 digoxin and, 371-373  
 verapamil and, 373
- Catecholamines, for cerebral perfusion, 243  
 in pediatric patient, 371  
 role of, in chronic heart failure, 601
- Catheter(s). See also *Cannulation, arterial*.  
 arterial, complications and management with, 557-562  
 intrapleural, postesophagagastrectomy, 181
- Cell counts, in inflammation and coagulation, 425-427
- Cenotoxin. See *Antiendotoxin antibody(ies), HA-1A*.
- Central nervous system (CNS), in pediatric patient, 373  
 in disseminated intravascular coagulation, 402
- Cephalosporins, resistance to, 317  
 structures of, 316  
 trade names of, 318
- Cerebral perfusion, definition of, 241  
 hypotensive agents for, 243-244  
 importance of, 243  
 stimulation of, pharmacotherapy in, 243-244  
 vasoactive agents for, 243-244
- CHDs. See *Congenital heart defects (CHDs)*.
- Chest physiotherapy, in flail chest injury, 674  
 in pulmonary contusion, 678
- CHF. See *Chronic heart failure (CHF); Congestive heart failure (CHF)*.
- Children, nutritional support of, 65-78  
 administration of, 67, 70-71  
 assessment for, 66-68  
 energy needs and, 68  
 enteral, 67, 70, 76  
 in bronchopulmonary dysplasia, 72-74, 76  
 in chronic-critical illness, 72-73  
 in congenital heart defects, 74-76  
 in trauma, 70-72  
 macronutrients in, 69  
 micronutrients, 69  
 parenteral, 67, 70  
 versus adult, 65-66  
 starvation and stress response in, 69-70
- Christmas disease. See *Hemophilia(s), factor IX deficiency*.
- Chronic heart failure (CHF), 569-672  
 cardiomyoplasty for, 627-633  
 epidemiology of, 569-573  
 incidence of, 570, 627  
 mechanical support in, pre-transplant, 649-659  
 mortality from, 572  
 myocardial revascularization for, 619-626  
 neurohormonal activation in, 599  
 renin-angiotensin-aldosterone system in, 600-601  
 sympathetic nervous system in, 599-600  
 pharmacotherapy for. See also *named type, e.g., Diuretic(s)*.  
 diuretics in, 581-585  
 evolution of, 575  
 inotropics in, positive, 589-597  
 neurohormonal agents in, 599-608  
 nursing implications of, 585  
 objectives in, 575  
 pathophysiologic processes and, 576  
 vasodilators in, direct-acting, 576-581  
 prevalence of, 570-571  
 quality of life with, 661-670  
 risk factors for, 571  
 sudden cardiac death from, 609-617  
 transplantation for, 635-648
- Chronic obstructive pulmonary disease (COPD), malnutrition in, 58
- Chylomicrons, 436-437
- Chylothorax, postesophagagastrectomy, 182
- Circulatory overload, transfusion-induced, 552
- Citrate toxicity, transfusion-induced, 552
- Clotting cascade, in coagulation, 391-395  
 in disseminated intravascular coagulation, 398-399
- Clotting factors, in fulminant hepatic failure, 146
- CMV. See *Cytomegalovirus (CMV)*.
- CNS. See *Central nervous system (CNS)*.
- Coagulation. See also *Hemostasis, control mechanisms in*.  
 assessment of, 425-426  
 blood vessels in, 309  
 clotting cascade in, 391-395

- factor X11a in, 392-395
  - factor XI in, 392-395
  - kallikrein in, 392-395
  - pathways in, 391-394
  - thrombin production in, 394-395
  - clotting factors in, 454-455, 460
    - replacement of, 469
  - endothelium in, vascular, 309
  - fibrinolytic system in, 395-396
  - inflammation and, assessment of, circulating inflammatory mediators in, 427
    - host defenses in, 427-428
    - laboratory values in, 425-427
    - tissue ischemia in, 425
  - cascades in, extrinsic and intrinsic, 416
    - in disseminated intravascular coagulation, 423-425
    - in multiple organ dysfunction syndrome, 419-421
    - in postischemic reperfusion injury, 421-423
    - mediators of, 414-419
  - inhibitors of, alpha<sub>2</sub>-antiplasmin, 397
    - antithrombin III, 396
    - plasminogen activators inhibitor type 1, 397
    - protein C and protein S systems, 396-397
    - thrombin, 397
  - in reperfusion injury, postischemic, 423-424
  - lipoprotein(a) in, 435-443. See also *Lipoprotein(a)*.
  - pathways in, 391-394, 453-455, 460-461, 526-527
  - plasma factors needed for, 463
  - platelet plug formation in, 390-391
  - vasoconstriction in, 309
  - vasospasm and platelet plug formation in, 453
  - Coagulation cascade, pathways in, extrinsic, 394
    - intrinsic, 391-393
    - thrombin production in, 394-395
  - Coagulation factor, deficiency of, 466-468
    - replacement of, 469
  - Coagulopathy(ies). See also *Coagulation*.
    - acquired, 453-458
      - from fulminant hepatic failure, 145-146, 149
      - from liver disease, 456-457
      - from pancreatitis, acute, 194
      - from renal disease, 457-458
      - from vitamin K deficiency, 455-456
    - congenital, 445-452
      - blood vessels in, 445-446
      - in afibrinogenemia, 452
      - in Ehlers-Danlos syndrome, 446
      - in hemophilias, 447-451. See also *Hemophilia(s)*.
      - in hereditary hemorrhagic telangiectasia, 445
      - in Kasabach-Merritt syndrome, 446
      - in von Willebrand disease, 446-447
      - plasma phase in, 447-451
      - platelet phase in, 446-447, 451
      - uncommon, 451-452
    - of pregnancy, 475-487
      - disseminated intravascular coagulopathy, 481-483
        - abruptio placentae and, 482-483
        - amniotic fluid embolism and, 483
        - preeclampsia and, 483
      - HELLP syndrome, 475-481
      - hemolytic-uremic syndrome, 484
      - thrombocytopenia, 483-484
      - thrombocytopenic purpura, 484
      - von Willebrand's syndrome, 484-485
    - postoperative, 459-473
      - blood replacement for, 468
      - coagulation factor replacement for, 469
      - differential diagnosis of, 464-468
      - from coagulation factor deficiency, 466-468
      - from platelet defects, 466
        - from vascular integrity disruption, 466
        - hyperfibrinolysis, 468
        - management of, 466-468
        - perioperative contribution to, 463-464
        - pharmacotherapy for, 468-470
        - platelet infusion for, 468-469
        - prevention of, preoperative evaluation in, 461-463
- Colony stimulating factors, cost of, 380
  - for septic shock, 334-335
- Complement, in coagulation and inflammation, 414-415
- Congenital heart defects (CHDs), in children, nutritional support in, 74-76
  - malnutrition in, 58
- Congestive heart failure (CHF), acute, diastolic dysfunction in, 261-262, 267-268
  - pharmacotherapy for, 261-269
  - stabilization in, 262-263
  - systolic failure in, 261-267
- CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study), 602-604
- Constipation, chronic, in diabetes mellitus, 53
- Continuous positive-airway pressure (CPAP), in adult respiratory distress syndrome, 728
- Contusion(s), from blunt chest injuries, cardiac, 681
  - pulmonary, 676-678
- Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), 602-604
- COPD (chronic obstructive pulmonary disease), malnutrition in, 58
- Coronary artery bypass grafting (CABG), in left ventricular dysfunction, 619-626
  - candidate for, ideal, 622
  - heart transplantation versus, 624
  - mortality and morbidity with, 622-623
  - myocardial viability and, 621
  - operative techniques in, 622
  - results of, long-term, 623
  - survival prediction and, 621-622
- Corticosteroids, in septic shock, 335
- Cost, of colony stimulating factors, 380
  - of drugs, case studies of, 378-379
    - ethics and, 379-382
    - savings in, 222
  - of erythropoietin, 380, 382
  - of thrombolytic agents, 380
- Coumadin, enteral nutrition and, interaction with, 35
- CPAP. See *Continuous positive-airway pressure (CPAP)*.
- CPR. See *Cardiopulmonary resuscitation (CPR)*.
- Creatinine-height index, 11-12
- Critical care unit, treatment outcomes management and, guidelines for, 747, 750-752
- Crush injury, thoracic, 687-688
- Cryoprecipitate, composition of, 548-549
  - in hemophilia, 450
  - indications for, 549
- Cryptosporidium, diarrhea from, 122
- Cytochrome P450, in drug metabolism, in children, 368-369
- Cytomegalovirus (CMV) infection, diarrhea from, 123
  - posttransplantation, of small intestine, 212
  - transfusion-induced, 551
- DDAVP. See *Desmopressin acetate (DDAVP)*.
- Desmopressin acetate (DDAVP), for coagulopathy, postoperative, 469-470
- Diabetes mellitus, chronic heart failure and, 571
  - classification of, insulin-dependent, 47-49
  - non-insulin dependent, 48-50

- Diabetes mellitus (*Continued*)  
 gastrointestinal disorders in, 52-53  
 in critically ill patient, nutritional support for, 51-53  
   indications for, 51, 53  
   protocols for, 53-54  
   stress response in, 49-50  
   nutritional support in, 47-56  
   pathophysiology of, 47  
 Diabetic ketoacidosis (DKA), 48, 51  
 Dialysis, nutritional management in, 88-90  
   delivery problems in, 93  
   dietician-nurse relationship in, 92-93  
   intradialytic, 89-90  
   intraperitoneal, 90  
   types of, 87-88  
 Diarrhea, chronic, in diabetes, 53  
   HIV/AIDS-related, bacterial, 122-123  
   infectious and noninfectious, 121-123  
   protozoan, 122  
   viral, 123  
   posttransplantation, of small intestine, 212  
 Diastolic dysfunction, in congestive heart failure beta-blockers for, 267  
   calcium channel blockers for, 267-268  
   pathology of, 261-262  
   venodilators for, 267  
   verapamil for, 268  
 Diazepam (Valium), in thoracic trauma, 705-706  
 DIC. See *Disseminated intravascular coagulation (DIC)*.  
 Digoxin, in pediatric versus adult patient, dosage of, 371-373  
   toxicity of, 372  
 Dilantin. See *Phenytoin (Dilatin)*.  
 Disseminated intravascular coagulation (DIC), 389-410  
   antithrombin III in, 503-504  
   characterization of, 389-390  
   clinical presentation and assessment of, multiple organ dysfunction syndrome in, 402  
   systems in, 401-402  
   coagulation and inflammation in, 423-425  
   etiology of, 389, 481-482  
   in pregnancy, 482-483  
   laboratory data in  
     alterations in, 403-404  
     new tests for, 404  
   management of, antithrombin III concentrate in, 406  
   aseptic technique and universal precautions, 405  
   blood component replacement therapy for, 405  
   fibrinolytic inhibitors in, 406  
   goals in, 404  
   hemodynamic monitoring in, 407  
   hemostatic cofactor replacement in, 406  
   heparin for, 405-406  
   investigational therapies in, 406  
   maintenance of organ viability in, 406-407  
   medical history and, 407  
   nutrient delivery in, 407  
   oxygen supply and transport in, 407-408  
   removal of pathologic trigger, 404  
   restoration of balance in, 405-406  
   pathophysiology of, 398-401  
   clotting cascade stimulation in, 398-399  
   hemorrhage in, 400-401  
   thrombosis in, 399-400  
 Distraction, in pain management, 719-720  
 Distribution, drug, in adults, 230-231  
   in children, 368  
 Diuretic(s), for congestive heart failure, acute, 262-263  
   commercially available, 582  
   distal, thiazides, 583  
   future of, 584-585  
   aquaretics, 585  
   atriopeptidase inhibitors, 585  
   loop, differences in, 583-584  
   mechanism of action of, 583-584  
   mechanism and site of action of, 581-582  
   potassium-sparing, 583  
   proximal tubular, 584  
   resistance to, 584  
   in pediatric patient, 370  
 DKA (diabetic ketoacidosis), 48, 51  
 Dobutamine (Dobutrex), for cerebral perfusion, 243  
   for chronic heart failure, 591-592  
   long-term use of, 593  
   for congestive heart failure, acute, 264-265  
   in pediatric patient, 371  
 Dobutrex. See *Dobutamine (Dobutrex)*.  
 Donor(s), cardiac, availability of, 635-636  
   recipient's feelings towards, 667  
   selection of, 636  
   small intestine, 204  
 Dopamine, for chronic heart failure, 591-592  
   for congestive heart failure, acute, 266  
   in pediatric patient, 371  
   in resuscitation, 252-253  
 Dopexamin, for chronic heart failure, investigational, 594  
 Doxacurium, 304  
 Drains, postesophagogastric, 181-182  
 Duodenum, trauma to, blunt, 133-134  
 Dysphagia, HIV/AIDS-related, 123-124  
   in esophageal cancer, 177  
   postesophagogastric, 183  
 Dysrhythmias, in fulminant hepatic failure, 145, 148  
 EACA (epsilon-aminocaproic acid), for coagulopathy, 469-470  
 ECMO. See *Extracorporeal membrane oxygenation (ECMO)*.  
 Edema, in fulminant hepatic failure, cerebral, 144  
   pulmonary, 145  
 EERT (emergency room resuscitation thoracotomy), 692  
 Ehlers-Danlos syndrome, 446  
 Elderly, chest trauma in, 735-740  
   epidemiology of, 735-736  
   mortality from, 736-737  
   respiratory function and, 737-738  
   therapeutic issues in, 738-739  
   falls versus vehicular accidents, 736, 739  
   pneumonia risk in, 739  
   stress and, 739  
   types of, 736  
 Electrolytes, in nutritional support, 31-36  
   in resuscitation, 255, 258  
   management of, in intensive care patient, 31-36  
   monitoring of, during diuretic therapy, 583, 585  
   replacement of, in pancreatitis, acute, 196-197  
 Embolectomy, for mesenteric ischemia, 174-175  
   for pulmonary thrombosis, 495  
 Embolism(s) See also under *Thromboembolism(s)*.  
   air, 496  
   amniotic fluid, 483  
   cerebral, 526  
   fat, 495  
   formation of, 490-491  
   pulmonary, after bone marrow transplantation, 538  
   septic, 496  
 Emergency room resuscitative thoracotomy (ERRT), 692  
 Enalapril, for chronic heart failure, mortality rates and, 572



- hydalazine-isosorbide dinitrate versus, 581
- Encephalopathy, hepatic, 42, 143-144, 148
- Endothelial cells, in coagulation and inflammation, 415-418
- Endotracheal tube, care of, 278
- effect of, on aerosol therapy, 274-277
- End-stage renal disease (ESRD), clinical signs of, 82-84
- development of, 84-85
- diet in, 82-83, 85-87
- Energy, expenditure of, in child, 66-67, 69
- nutrition and, in adult, 12-14
- Enoximone, for chronic heart failure, 595
- Enteral nutrition, access devices for, pediatric, 67
- composition of, 25-28
- in selected formulations, 27
- for diabetic patient, blood glucose control and, 53-55
- formulas available for, 52
- insulin administration and, 54-55
- nursing considerations and, 55
- gut mucosa and, 23-25
- immune function and, of gastrointestinal tract, 113-114
- in cardiopulmonary disease, 61
- in pancreatitis, 40-41
- acute, 198
- pediatric, 70
- devices for, 67
- strategies for, 76
- postesophagogastrctomy, 181
- Epidural space, analgesia in, 292-293
- Epinephrine, in resuscitation, 250-253
- high-dose, 251-252
- Epsilon-aminocaproic acid (EACA), for coagulopathy, 469-470
- ERRT. See *Emergency room resuscitative thoracotomy (ERRT)*.
- Erythropoietin, cost of, 380, 382
- Esophageal varices, bleeding, **153-162**
- balloon tamponade for, esophagogastric, 156-157
- complications from, 158-159
- endoscopy of, 155
- liver transplantation for, 161
- pathophysiology of, 153
- pharmacotherapy for, 155-156, 159
- prevention of, 159-161
- sclerotherapy for, 155, 159
- surgery for, 157-160
- volume replacement in, 154-155
- Esophagogastrctomy, **177-184**
- approaches to, abdominal, 178-179
- thoracoabdominal, 179
- transhiatal, 179-180
- indications for, 178
- postoperative care and, 180
- preoperative preparation for, cardiovascular, 178
- nutritional, 178-179
- pulmonary, 178
- therapeutic, 178
- recuperative care and, cardiovascular, 180
- nutrition in, 181
- pain management in, 181
- respiratory, 180-181
- tubes and drains in, 181-182
- wound healing in, complications of, 182
- secondary procedures and, 180
- Esophagus. See also *Tracheobronchial tree*.
- disruption of, 695
- esophagogastrctomy of, **177-184**
- perforation from, 694
- trauma to, diagnosis of, 132
- management of, 132-133
- mechanism of, 130, 132
- varices of, bleeding, **153-162**
- ESRD. See *End-stage renal disease (ESRD)*.
- Ethics, drug dilemmas in, **377-382**. See also *Cost, of drugs*.
- case studies of, 378-379
- cost issues in, 379-382
- in decision making, 378-379
- institutional committees and, 20-21
- issues in, in renal failure, 82-87, 91-92
- nutritional and, withholding and withdrawal of, 17-18, 20
- principles of, 19-20, 377-378
- termination of treatment and, 18-19
- Etomidate (Amidate), in thoracic trauma, 705
- Excretion, renal, of drug, in children, 369-370
- Exercise program, after cardiac transplantation, 640-641
- Extracorporeal membrane oxygenation (ECMO) system, in adult respiratory distress syndrome, 729-731
- for cardiac donor, 653
- for cardiac transplant recipient, 651-653
- Extubation, in chest trauma, 707-708
- Factor concentrates, transfusion of, 548
- evaluation of, 555
- Factor replacement, in hemophilia, 450
- Factor VIII, in hemophilia, 447-450. See also *Hemophilia(s), factor VIII deficiency*.
- Falls, versus motor vehicle accidents, in elderly, 736, 739
- Fat, in refeeding, 101
- metabolism of, 98
- requirement for, in cardiopulmonary disease, 60
- in children, 68
- Fatty acids, polyunsaturated, immune response modulation and, 117
- Felodipine, for chronic heart failure, 579
- Fenoldopam, for arterial vasodilation, 579
- Fentanyl, for analgesia, 293
- Fibrinogen. See also *Cryoprecipitate*.
- Fibrinolysis, in hemostasis, 460-462
- Fibrinolytic inhibitors, for disseminated intravascular coagulation, 406
- Fibrinolytic system, 395-396
- Fibrosis, pulmonary, after bone marrow transplantation, 537
- Fistula, pancreatic, from trauma, 136-137
- FK-506, immunosuppression with, 206-207
- Flail chest injury, 675-676
- Fluid, replacement of, in esophageal varices, bleeding, 154-155
- in pancreatitis, acute, 196
- Fractures, in blunt chest injury, 674-676, 682
- flail chest, 675-676
- of thoracic cage, 675
- Free radicals, formation of, in reperfusion injury, postischemic, 422
- Fresh frozen plasma, administration of, 548, 554
- complications from, 548
- usage guidelines for, 547-548
- Fulminant hepatic failure, **141-151**
- definition of, 141
- etiology of, hypoperfusion, 143
- infectious, 141-142
- pharmacologic and toxic, 142-143
- liver transplantation for, 149-150
- management of, 147-149
- manifestations and treatment of, acid-base, 146

- Fulminant hepatic failure (*Continued*)  
 cardiovascular, 144-145, 148  
 gastrointestinal, 147  
 hematologic, 145-146, 149  
 infectious, 147, 149  
 metabolic, 146-147, 149  
 neurologic, 143-144, 148  
 pulmonary, 145, 149  
 renal, 145, 149
- Furosemide, for intracranial pressure reduction, 242
- Gallstones, pancreatitis from, acute, 186
- GALT (gut-associated lymph tissue), immune function of, 110
- Gastric tonometry, in perfusion assessment, 425
- Gastroenterology, 107-213
- Gastrointestinal tract, anatomy of, 171-172  
 immunologic role of, 107-120  
 bacteria in, 110, 113  
 cellular, 112  
 humoral, 110-112  
 liver in, 112-113  
 lymphoid tissues in, 110-111  
 macrostructure in, 107-109  
 microstructure in, 107-109  
 modulation of, nutritional, 113-118  
 mucosa in, 108-110  
 secretions in, 110  
 in disseminated intravascular coagulation, 402  
 in HIV/AIDS, anorectal disease, 124-125  
 infections in, 124-125  
 trauma to, 127-140  
 blunt versus penetrating, 128  
 colonic, 137-139  
 complications of  
 duodenal, 133-135  
 esophageal, 130-133  
 evaluation of, 128-132  
 gastric, 131, 133  
 historical perspective in, 127-128  
 monitoring in, 130-132  
 nursing assessment in, 129  
 pancreatic, 135-137  
 small bowel, 135
- Gastroparesis, in diabetes, 52-53
- Giardia*, diarrhea from, 122
- Glomerular filtration rate, in pediatrics, 369-370
- Glucose, blood, enteral nutrition and, 53-55  
 total parenteral nutrition and, 51, 53-54  
 metabolism of, 51-52  
 monitoring of, during nutritional support, 53-55
- Glucuronidation, of drugs, in pediatrics, 369
- Glutamine, immune response and, modulation of, 114-115  
 in enteral nutrition, 25-26  
 in refeeding, in hypermetabolism, 102
- Graft(s), occlusion of, lipoprotein(a) and, 439-440  
 rejection of, heart, 641-643  
 small intestine, 211
- Graft-versus-host disease, after bone marrow transplantation, 535-538  
 acute versus chronic, 535  
 human lymphocyte antigen disparity in, 535  
 incidence of, 536  
 lung disease and, 537-538  
 treatment of, 536
- Granulocyte colony stimulating factor (G-CSF), 550
- Granulocyte/monocyte colony stimulating factor (GM-CSF), 550
- Granulocytes, transfusion of, complications from, 549  
 dosing of, 549-550  
 evaluation of, 555  
 indications for, 549
- Great vessels, blunt injury to, 682-684  
 penetrating injury to, 691-693  
 thoracotomy for, 691-692
- Guns and firearms, chest injury from, cavitation, 688-689  
 combustion, 689  
 tissue crush, 687-688
- Gut-associated lymph tissue (GALT), immune function of, 110
- Gut mucosa, bacteria and, translocation of, 24-25  
 in critical illness, 24-25  
 malnutrition and, 24  
 normal, 23-24  
 nutritional support of, 25
- H<sub>2</sub> antagonists. *See Histamine-2 (H<sub>2</sub>) antagonists.*
- Harris-Benedict equation, 12
- HDLs (high-density lipoproteins), 436-437
- Heart. *See also Cardiac transplantation; Cardiopulmonary disease.*  
 malnutrition effect on, 57-58
- HeartMate 1000 LVAD, 655-656
- Heart rate, variability of, sudden cardiac death from, 612-614
- Height-body weight, 6-7
- HELLP syndrome, and coagulopathies of pregnancy, 475-487. *See also Coagulopathy(ies), of pregnancy.*  
 definition of, 475  
 etiology of, 475  
 impact on pregnancy, 478-479  
 laboratory values in, 478-479  
 management of, antihypertensive therapy for, 481  
 hemodynamic monitoring in, invasive, 479  
 maternal and fetal assessments in, 479-480  
 medical, 479  
 MgSO<sub>4</sub> in, 479-481  
 nursing, 479-481  
 pathophysiology of, 475-478
- Hemarthrosis, in hemophilia, 448
- Hematoma, intramural duodenal, 134
- Hematuria, in hemophilia, 449
- Hemodialysis, 87-88
- Hemodilution, coagulopathies from, postoperative, 463
- Hemodynamic monitoring, invasive, in HELLP syndrome, 479
- Hemodynamics, evaluation of, during diuretic therapy, 585
- Hemoglobin, in inflammation and coagulopathies, 429
- Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. *See HELLP syndrome.*
- Hemolytic-uremic syndrome, in pregnancy, 484
- Hemophilia A. *See Hemophilia(s), factor VIII deficiency.*
- Hemophilia B. *See Hemophilia(s), factor IX deficiency.*
- Hemophilia(s), 447-451  
 factor VIII deficiency, 447-450  
 definition of, 447-448  
 factor replacement for, 450  
 inhibitors of, acquired, 449-450  
 manifestations of, 448-449  
 treatment of, 450  
 factor IX deficiency, 450  
 factor XI deficiency, 451



- Hemorrhage(s), assessment of, 425-426  
 in disseminated intravascular coagulation, 400-401  
 in hemophilia, intracranial, 448  
 of peripheral nervous system, 448  
 post-thrombotic, intracerebral, 515  
 intracranial, 514, 516-517  
 subarachnoid, 515-516
- Hemosiderosis, transfusion-induced, 552
- Hemostasis. See also *Coagulation*.  
 evaluation of, tests for, 464-466  
 inhibitors of, 499-500  
 mechanisms in, coagulation inhibitors, 396-397  
 coagulation pathways, 391-394, 454-455, 460-461  
 fibrinolysis, 460-462  
 platelet plug formation, 453, 459-460  
 vasoconstriction, 453, 459  
 pharmacotherapy and, 469-470  
 serine proteases in, 499-500  
 thrombolysis in, 356
- Hemothorax, from penetrating injury, 693-694
- Heparin, administration of, 519  
 complications with, 519-520  
 for disseminated intravascular coagulation, 405-406  
 in antithrombin III activity, 499-500  
 mechanism of action of, 519  
 thrombocytopenia from, 520-521  
 uses of, 519
- Heparinization, coagulopathies from, postoperative, 463-464
- Heparinoids, for stroke, 525-529. See also *Stroke*, *ischemic*.  
 advantages of, 526  
 versus heparin, 526  
 low molecular weight, 526  
 non-neurologic uses of, 526-527  
 prototype, ORG10172, 527-529. See also *ORG10172*.
- Hepatic disease. See also *Fulminant hepatic failure*.  
 acute-on-chronic, 42  
 fulminant, 41-42  
 liver transplantation for, 42-43  
 nutrition and, assessment of, 41  
 needs for, 37-38
- Hepatitis, fulminant hepatic failure from, 141-142  
 transfusion-induced, 551
- Hepatobiliary disease, HIV/AIDS-related, 124
- High-density lipoproteins (HDLs), 436-437
- Histamine-2 (H<sub>2</sub>) antagonists, for stress ulcer, 167, 325-331  
 prophylactic, for stress-related mucosal damage, 327-329
- HIV/AIDS, from transfusions, 551  
 gastrointestinal tract and, 121-126
- HNKC (hyperosmolar nonketotic coma) syndrome, 49-50
- Host defenses, assessment of, 427-428
- Human IgM monoclonal anti-lipid A antibody(ies), E5, 337  
 HA-1A, 336-337
- Hydralazine, oral, for congestive heart failure, acute, 266
- Hydralazine-isosorbide dinitrate, versus enalapril, 581  
 versus prazosin, 580-581
- Hypercholesterolemia, after cardiac transplantation, 646
- Hypercoagulability, in thrombus formation, 490
- Hyperfibrinolysis, 468
- Hyperglycemia, from enteral formulas, 52  
 from total parenteral nutrition, 51-52  
 in pancreatitis, 40, 192
- Hyperkalemia, from angiotensin-converting enzyme inhibitors, 604  
 transfusion-induced, 552
- Hyperlipidemia, in pancreatitis, 40
- Hypermetabolism, 97-105. See also *Metabolism*.  
 assessment of, nutritional and metabolic, 99-102  
 stress stratification in, 100-101  
 feeding regimen in, 101-103  
 injury and, response to, 97-99
- Hyperosmolar nonketotic coma (HNKC) syndrome, 49-50
- Hypertension, after cardiac transplantation, 645  
 chronic heart failure and, 571  
 portal, beta blockers for, 159  
 esophageal varices from, 153  
 etiology of, 153-154  
 in fulminant hepatic failure, 147
- Hypocalcemia, in fulminant hepatic failure, 147, 149  
 in pancreatitis, 40, 192-193
- Hypoglycemia, in fulminant hepatic failure, 146
- Hypokalemia, in fulminant hepatic failure, 146-147, 149
- Hypomagnesemia, in fulminant hepatic failure, 147, 149
- Hyponatremia, in fulminant hepatic failure, 146, 149
- Hypophosphatemia, 62  
 in fulminant hepatic failure, 147, 149
- Hypotension, from angiotensin-converting enzyme inhibitors, 604  
 in fulminant hepatic failure, 144-145
- Hypothermia, coagulopathies from, postoperative, 463  
 transfusion-induced, 552
- Ibopamine, for chronic heart failure, investigational, 593
- Ibuprofen, for inflammation and coagulopathies, 430
- IDDM. See *Insulin-dependent diabetes mellitus (IDDM)*.
- IGT (impaired glucose tolerance), 47
- IL-1. See *Interleukin-1 (IL-1)*.
- Imagery, in pain management, 720
- Immune response, gastrointestinal tract in, 107-120. See also *Gastrointestinal tract*, *immunologic role of*.
- Immunonutrients, arginine, 115-117  
 glutamine, 114-116
- Immunosuppression, after transplantation, cardiac, 643-644  
 small intestine, 206-207, 212  
 agents for, nutrition and, 91
- Immunotherapy. See also *Antitendotoxin therapy*.  
 for sepsis, mechanisms of, 337  
 role of, 336  
 studies of, 336-337  
 with antiendotoxins, 335-337, 347-352, 354  
 with immunoglobulins, 335-337  
 targets for, 333-343
- Impaired glucose tolerance (IGT), 47
- Infection(s), after bone marrow transplantation, 534  
 cardiac, 539  
 hepatic, 539-540  
 respiratory, 536-537  
 after cardiac transplantation, 643, 645  
 after cardiomyoplasty, 632  
 after implantation of ventricular assist devices, 657  
 HIV-associated, gastrointestinal, 121-126  
 nosocomial, antibiotics for, 318-320  
 administration of, 320-321  
 bacteremia, 320-321  
 pathogens in, 315  
 pneumonia, 318-320  
 sites of, 315, 321  
 susceptibility to, 313  
 urinary tract, 320
- Inflammation, and coagulation. See also *Coagulation*.  
 assessment of, parameters in, 425-428

Inflammation (*Continued*)

- management of, increase in oxygen supply and demand, 428-429
  - investigational therapies for, 429-430
    - nutritional support, 429
  - measurements of, 427
  - mediators of, 411-414
  - physiology of, 411-413
  - relationship and pathophysiologic potential of, 414-419
    - syndromes associated with, 419-425
    - triggers of, 412
- in reperfusion injury, 423-424
- Inflammation cascade, 412-413
  - mediators in, 412-414
  - triggers of, 412
- Infusion, continuous, of neuromuscular blocking agents, 301
- Injection, intermittent bolus, of neuromuscular blocking agents, 300-301
  - of analgesics, intermittent intravenous, 290-291
  - intramuscular, 290
- Inotropic agent(s), for chronic heart failure, 589-597
  - actions and effects of, 589-590
  - beta-adrenergic agonists, 591-593
  - digitalis glycosides, 590-591
  - goals of, 589
  - phosphodiesterase inhibitors, intravenous, 594
  - oral, 595
- Insulin-dependent diabetes mellitus (IDDM), 47-49
- Insulin, enteral nutrition and, 54-55
  - total parenteral nutrition and, 53-54
- Interleukin-1 (IL-1), for septic shock, 338-339
  - in coagulation and inflammation, 417
- Intracranial pressure, increase in, management of, 242-243
  - pathophysiology of, 240-241
  - reduction of, pharmacotherapy for, 241-242
- Intrathecal space, analgesia in, 292-293
- Intubation, for tracheobronchial tears, 680
  - in chest trauma, 697-699
- Ischemia, atherosclerotic, 525
  - mesenteric, acute, 171-175
    - causes of, 172
    - diagnosis of, 173-174
    - response to, cellular, 172-173
    - treatment of, pharmacologic, 174
    - surgical, 174-175
  - tissue, assessment of, 425-426
- Isoproterenol, in resuscitation, 254, 258
- Isosorbide dinitrate, for acute congestive heart failure, 266-267
  - with hydralazine, for chronic heart failure, 580-581
- Isosporabelli*, diarrhea from, 122
- Justice, 20, 377-378
- Kabikinas (streptokinase), 359-360
- Kasabach-Merritt syndrome, 446
- Ketamine, in thoracic trauma, 705
- Kidneys, excretion via, in pediatric patient, 369-370, 373
  - function of, 79-81
  - transplantation of, nutritional issues in, 90-92
- Kwashiorkor, 3
- Latissimus dorsi muscle, in cardiomyoplasty, 628-630
- LDLs (low-density lipoproteins), 436-437
- Left ventricular dysfunction, congestive heart failure and, 619-620
  - definition and causes of, 620-621
  - myocardial revascularization for, 621-623
  - natural history of, 621
  - percutaneous transluminal coronary angioplasty for, 623
    - sudden cardiac death from, 625
- Lidocaine, for seizures, 239
  - in resuscitation, 254, 256
- Life-sustaining treatment, 17
- Lipase, serum, in pancreatitis, 190
- Lipids, in enteral nutrition, 28
- Lipoprotein(a), gender and, 439
  - graft occlusion and, 439-440
  - in atherogenesis, 439-440
  - plasminogen and, 437-438
  - reduction of, diet in, 441
    - education in, 440-441
    - pharmacotherapy in, 441-442
  - role of, in coagulation, 435-443
- Lipoprotein(s), apoproteins, 436-437
  - chylomicrons, 436-437
  - classification of, 435-437
  - definition of, 435
  - high-density, 436-437
  - lipoprotein(a), 437-440
  - low-density, 436-437
  - schematic of, 436
  - very low-density, 436-437
- Liver. See also *Fulminant hepatic failure*; *Hepatic disease*.
  - diseases of, coagulopathies from, 456-457
  - dysfunction of, after bone marrow transplantation, 539-540
    - in veno-occlusive disease, 540
  - infections of, HIV/AIDS-related, 124
  - injury to, drug-induced, 540
  - transplantation of, 149-150
- Low-density lipoproteins (LDLs), 436-437
- Lungs. See also *Cardiopulmonary disease*; *Cardiopulmonary resuscitation (CPR)*.
  - penetrating injury to, 692-694
  - malnutrition and, effect of, 57-58
- Macrophages, in coagulation and inflammation, 416-417
- Magnesium, in total parental nutrition, 33
- MAI. See *Mycobacterium avium intracellulare (MAI)*.
- Malabsorption syndromes, vitamin K deficiency from, 456
- Malnutrition. See also *Starvation*.
  - effects of, on heart and lungs, 57-58
  - gut mucosa and, 24
  - in cardiopulmonary disease, detection of, 58
    - with and without catabolism, 58-59
  - in hepatic disease, 43
  - protein-calorie, 2-3
  - response to, of end organs, 98
  - vitamin K deficiency from, 455-456
- Mannitol, for intracranial pressure reduction, 241-242
- Marasmus, 2-3
- McGill pain questionnaire, 715-716
- MDI. See *Metered-dose inhaler (MDI)*
- Medication, errors in, 222-223
- Metabolism. See also *Hypermetabolism*.
  - in renal failure, 84
  - of drug, in pediatrics, 368-369

- Metered-dose inhaler (MDI), for aerosol therapy, adapters for, 273, 276  
 spacer device for, 274-275  
 versus nebulizer, 273-274
- Midarm muscle circumference, 7
- Midazolam (Versed), in thoracic trauma, 705-706
- Milrinone, for chronic heart failure, 594-595
- Mivacurium, 304
- MODS. See *Multiple organ dysfunction syndrome (MODS)*.
- Molsidomine (Molsidomine), 578
- Monobactams, resistance to, 317  
 structures of, 316  
 trade names of, 318
- Monoclonal antibodies, for inflammation and coagulopathies, 429-430
- MSOF (multisystem organ failure), after bone marrow transplantation, 540-541
- Mucous membranes, analgesia via, 293
- Multiple organ dysfunction syndrome (MODS),  
 coagulation and inflammation in, 419-421  
 coagulation and inflammation in, role of, 420  
 definition of, 419  
 inflammation versus infection in, 419-420  
 pathophysiology of, 420, 422
- Multisystem organ failure (MSOF). See also *Multi system organ disease (MSOD)*.  
 after bone marrow transplantation, 540-541
- Muscle relaxants, in trauma anesthesia, 706-707
- Mycobacterium avium intracellulare (MAI)*, diarrhea from, 122-123  
 hepatobiliary disease from, 124
- Myocardial infarction, acute, thrombolysis in, 358-360  
 reperfusion injury following, 424
- Myonecrosis, after cardiomyoplasty, 632
- Nebulizer, effect of, on aerosol therapy, 276-278
- Neomycin, for lipoprotein(a) reduction, 441-442
- Nephrotic syndrome, antithrombin III in, 504
- Nephrotoxicity, aminoglycoside, in pediatric patient, 373-374
- Neurohormonal agent(s), for congestive heart failure. See also *named class*.  
 angiotensin-converting enzyme inhibitors, 601-604  
 beta-blockers, 604-606
- Neurologic therapy, 237-246  
 for cerebral perfusion, 243-244  
 for intracranial pressure, reduction of, 241-242  
 for seizures, 238-239. See also *Anticonvulsant(s); Seizures; Status epilepticus*.
- Neurologic toxicity, after bone marrow transplantation, 540
- Neuromuscular blockade, agents for, 297-311.  
 administration of, 300-301  
 atracurium, 302-303  
 cautions with, 306  
 classification of, 298-300  
 complications with, 308  
 doxacurium, 304  
 drug interactions with, 306-307  
 monitoring of, 304-306, 308  
 neuromuscular transmission and, 297-299  
 pancuronium, 303-304  
 paralysis from, prolonged, 308  
 pipecuronium, 304  
 prophylactic measures with, 306  
 resistance to, 307-308  
 selection of, 300-301  
 succinylcholine, 301-302, 706-707  
 vecuronium, 303  
 indications for, 299-300  
 in mechanical ventilation, 297, 299  
 in thoracic trauma, 705-706
- Neutrophil count, 425-427
- Neutrophils, role of, in coagulation and inflammation, 416-417  
 in reperfusion injury, postischemic, 422
- Nicotinic acid, for lipoprotein(a) reduction, 441-442
- NIDDM. See *Non-insulin-dependent diabetes mellitus (NIDDM)*.
- Nipride. See *Nitroprusside (Nipride)*.
- Nitrates, for congestive heart failure, 578
- Nitrogen balance, in hypermetabolism, 100
- Nitroglycerine, for cerebral perfusion, 244  
 for congestive heart failure, acute, 264-266  
 for diastolic dysfunction, 267
- Nitroprusside (Nipride), for cerebral perfusion, 244  
 for chronic heart failure, 580  
 for congestive heart failure, acute, 264-265
- Non-insulin-dependent diabetes mellitus (NIDDM),  
 pathophysiology of, insulin insufficiency in, 48-49  
 insulin resistance in, 49, 51
- Nonopioid(s), acetaminophen, 289, 291  
 action of, 282-283  
 adverse reactions to, 287-288  
 gastrointestinal, 287-288  
 hematologic, 288  
 hypersensitivity, 288  
 renal, 288  
 dosage of, 289, 291  
 drug interactions with, 289  
 indications for, 284  
 nonsteroidal anti-inflammatory drugs, 289, 291  
 pharmacokinetics of, 285-286  
 salicylates, 289, 291
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 289, 291
- Norepinephrine, role of, in chronic heart failure, 601  
 in resuscitation, 252-253
- Novacor, 653-655
- NSAIDs (nonsteroidal anti-inflammatory drugs), 289, 291
- Nucleotides, in immune response modulation, 117-118
- Nutrition. See also *Enteral nutrition; Total parenteral nutrition (TPN)*.  
 assessment of, anthropometrics in, 4, 6-7  
 energy needs in, 12-14  
 history in, 3-4  
 laboratory studies in, 7-12  
 malnutrition and, 2-3  
 physical examination in, 4-6  
 starvation and, 1-2  
 in hypermetabolic patient, 97-103  
 in intensive care patient, with cardiopulmonary disease, 57-64  
 with diabetes mellitus, 47-56  
 with pancreaticobiliary disease, 37-45  
 with renal failure, 79-96  
 in intensive care unit, 1-16. See also *Malnutrition*.  
 assessment of, 17-21  
 drugs and, 31-36  
 electrolytes and, 31-36  
 enteral feeding and, 23-29  
 ethics and, 17-21  
 in the pediatric intensive care unit, 65-78  
 preoperative, for esophagogastrectomy, 178-179  
 status of, assessment of, 427  
 supportive, 429  
 after cardiac transplantation, 646

Nutrition (*Continued*)

- drug management in, 31-36
  - in cardiopulmonary disease, 61
  - in pancreatitis, 198
  - sodium in, 31-32

Occlusion, coronary. See *Myocardial infarction, acute*.

- peripheral arterial, urokinase for, 360-363

## Odynophagia, HIV-AIDS-related, 123-124

## Opiates, in thoracic trauma, 706

## Opioid antagonists, for septic shock, 339

Opioids. See also *Nonopioids*.

- adverse reactions to, 286-287
- classification of, 282-283
- dosage of, 290-291
- drug interactions with, 288-289
- indications for, 283-284
- mechanism and sites of action of, 282-283
- pharmacokinetics of, 284-285

## Oral contraceptives, effect on antithrombin III, 504

## ORG10172, activity of, 528

- administration of, 528
- adverse reactions to, 528
- description of, 527
- patient selection for, 528-529
- nursing role and, 528-529
- outcomes of, 528

## Overfeeding, 62

## Oxygen, demand for, immune system dysfunction and, 429

- supply of, tissue ischemia and, 428-429
- toxic metabolites of, in coagulation and inflammation, 417-418

## Oxygen saturation, arterial, in inflammation and coagulopathy, 429

Pain. See also *Analgesia*.

- acute, analgesia for, 281-295
- assessment of, behavioral, 715
  - physiologic, 715-716
  - verbal, 715
- consequences of, 716
- control of, in flail chest injury, 678
- effects of, 281
- in thoracic trauma, 713-722
- management of, cutaneous stimulation, 719
  - epidural analgesia, 717-718, 720
  - in pancreatitis, 197
  - in small intestine transplantation, 208
  - in substance abuser, 720
  - intrathecal analgesia, 718
  - local anesthetics, 719
  - nonsteroidal anti-inflammatory drugs, peripherally acting, 718-719
  - patient-controlled analgesia, 717
  - principles of, 717
  - psychologic therapies, 719-720
  - research in, 720
  - mechanisms of, 715-716
  - stimulants of, 716
  - transmission of, 281-282
- Pancreas, trauma to, 136-137
  - fistula from, 136-137
- Pancreatitis, acute, 185-202
  - classification of, 185
  - clinical signs of, 188-189

## complications of, cardiovascular, 192, 198-199

- central nervous system, 194
- hematologic, 194
- metabolic, 192-193
- pulmonary, 191, 197
- renal, 194
- retinopathy, 194-195
- septic, 193-194
- skin and joint, 194

## description of, 185

## diagnosis of, 189-191

## necrotizing, 189, 199

## nutrition in, altered, 38, 40

## needs in, 37-38

## pathogenesis of, 185-188

## pathophysiology of, 187-188

## Ranson criteria for, 38, 40

## in fulminant hepatic failure, 147

## management of, assessment in, prognostic, 195-196

## collaborative, 195

## nursing diagnoses in, 195

## stabilization in, 196-197

## supportive therapies in, 197-198

## surgical, 199-200

## systemic, 198-199

## Pancuronium, 303-304

## Papaverine hydrochloride, for mesenteric ischemia, 174

## Paraldehyde, for seizures, 239

## Partial thromboplastin component (PTC) deficiency. See

*Hemophilia(s), factor IX deficiency*.

## Patient-controlled analgesia (PCA), 292, 719

PCA. See *Patient-controlled analgesia (PCA)*.

## PEEP (positive end-expiratory pressure), 728

## Penetrating chest injury(ies), 687-694

## assessment of, airway, breathing, circulation in, 689-

## 690

## secondary survey in, 690

## cardiovascular, cardiac rupture, 690

## pericardial tamponade from, 690-691

## diaphragmatic, 695

## esophageal, 694-695

## from guns and firearms, 687-689

## cavitation, 688-689

## combustion, 689

## tissue crush in, 687-688

## from stab wounds, 691

## great vessel and aorta, 691-692

## mortality from, 687

## pulmonary, communicating pneumothorax, 693

## hemothorax, 693-694

## pneumothorax, 692

## tension pneumothorax, 692-693

## tracheobronchial, 694

## Penicillins, resistance to, 317

## structures of, 316

## trade names of, 318

## Pentoxifylline, for inflammation and coagulopathies, 430

## Percutaneous transluminal angioplasty (PTCA), 623-624

## Perfusion, assessment of, gastric tonometry in, 425

## Pericardial tamponade, from blunt chest injuries, 681

## in penetrating chest injury, 690-691

## Peritoneal lavage, diagnostic, in gastrointestinal trauma, 130

## in pancreatitis, 198

## Pharmaceutical care, in intensive care unit, 221-225

## concept of, 223-224

## drug-related problems in, 221-222, 224

## errors in, 221-223

## impact of, 224

## implementation of, barriers to, 224-225

- interventions in, 222-223
- model for, 224
- mortality and morbidity from, 224
- pharmacist role in, 222-223
- Pharmacodynamics. *See also Pharmacokinetics.*
  - definition of, 367
  - pediatric, 367-375
    - cardiovascular, 370-373
    - in central nervous system, 373
    - renal, 373-374
- Pharmacokinetics. *See also Pharmacodynamics; Serum drug concentration (SDC); Therapeutic drug monitoring.*
  - absorption in, 229-231
  - accumulation in, to steady state, 231-232
  - definition of, 227, 367
  - distribution in, 230-231
  - dosing regimens and, 231
  - elimination in, 230-231
  - in critical care, 227-235
  - models in, 228-230
  - pediatric, absorption in, 367-368
    - distribution in, 368
    - excretion in, renal, 369-370
    - metabolism in, 368-369
  - pharmacodynamics versus, 227
  - terms in, common, 234
  - therapeutic drug monitoring in, 227-229, 231-233
- Pharmacotherapy. *See Pharmaceutical care.*
- Pharmacy and therapeutics (P&T) committee, drug therapies and, 380, 382
- Phenytoin (Dilantin), for seizures, 238-239
- Phosphorous, in nutritional support, 33
- Pipecuronium, 304
- Plasma. *See Fresh frozen plasma.*
- Plasma phase, congenital coagulopathies in, 447-451
- Platelet phase, congenital coagulopathies in, 446-447, 451
- Platelet plug, formation of, in hemostasis, 453, 459-460
- Platelets, aggregation of, heparin-induced, 520-521
  - therapies for, 521
  - defects in, coagulopathy from, postoperative, 466
  - in coagulation and inflammation, 412-414, 418-419
  - in fulminant hepatic failure, 146
  - infusion of, postoperative, 468-469
  - in platelet plug formation, 390-391
    - aggregation in, 391
    - release reaction in, 391
    - shape change in, 390-391
  - transfusion of, evaluation of, 555
  - indications for, 547
  - storage and handling for, 546-547
- Pneumonia, after bone marrow transplantation, 537
  - in elderly, 739
  - nosocomial, antibiotics for, 319-320
    - drug-related, 330
    - pathogenesis of, 318-319
- Pneumonitis, interstitial, after bone marrow transplantation, 536-537
- Pneumothorax. *See also Hemothorax.*
  - communicating, from penetrating injury, 693
  - tension, from blunt injury, 679
  - from penetrating injury, 692-693
- Positive end-expiratory pressure (PEEP), in adult respiratory distress syndrome, 728
- Potassium, in nutritional support, 32-33
- Prealbumin, 9, 11
- Preeclampsia, disseminated intravascular coagulation and, 483
  - in coagulopathy of pregnancy, 483
  - pathophysiology of, 475-478
- Pregnancy, antithrombin III deficiency in, 505-506
  - coagulopathies of, 475-487
  - HELLP syndrome in, 475-481
  - preeclampsia in, pathophysiology of, 475-478
- Procainamide, in resuscitation, 254, 256
- Prostaglandins, endogenous, in stress ulceration, 165
  - exogenous, for stress ulceration, 167-168
- Protein, circulating, 8
  - in hypermetabolism, in refeeding, 102
  - metabolism of, 98-100
  - intake of, in dialysis patient, 88-89
  - in end-stage renal disease, 86-87, 91
  - levels, in hypermetabolism, 99-100
  - malnutrition and, 2-3
  - requirement for, in cardiopulmonary disease, 59-61
  - in children, 68
  - in pancreatobiliary disease, 37-38
  - retinol-binding, 10-11
- Protein C, deficiency of, congenital, 451
  - in venous thrombosis, 507
- Protein C system, in coagulation inhibition, 396-397
- Protein S, deficiency of, congenital, 451
  - in venous thrombosis, 507
- Protein S system, in coagulation inhibition, 396-397
- P&T (pharmacy and therapeutics) committee, 380, 382
- PTC (partial thromboplastin component deficiency). *See Hemophilia(s), factor IX deficiency.*
- Pulmonary embolism, diagnosis of, 491-493
  - embolectomy for, 495
  - formation of, 491
  - pharmacotherapy for, 494
  - prevention of, 492, 494, 496
  - signs and symptoms of, 492
  - vena caval interruption for, 494-495
- Pulsatile pump (ABIOMED BVS-5000 system), 653-654
- Purpura, thrombocytopenic, in pregnancy, 484
  - transfusion-induced, 552
- Quality of life, after cardiac transplantation, 666-668
  - feelings toward donors, 667
  - psychiatric factors in, 667-668
  - return to work, 666
  - versus non-cardiac transplantation, 668
  - conceptual frameworks of, 662
  - definitions of, 661-662
  - in chronic heart failure, 661-670
    - measurements of, instruments for, 663-664
    - issues in, 662-663
    - outcome, in heart failure, 664-666
    - in patients with heart assist devices, 666
    - research in, future, 668-669
- Ranson criteria, 38, 40
  - in pancreatitis, acute, prognostic, 196
- Red blood cells, transfusion of, acute hemolysis following, 550
  - administration in, 546, 552
  - storage and handling for, 545-546, 552
- REE (resting-energy expenditure), 10-13
- Reflux, esophageal, postesophagogastrectomy, 182-183
- Relaxation, in pain management, 719
- Renal disease, coagulopathies from, 457-458
- Renal failure. *See also Dialysis; Transplantation, kidney.*
  - acute, 81, 84
  - after bone marrow transplantation, 549
  - dialysis for, 87-88

Renal failure (*Continued*)

- nutritional issues in, 88-90, 92-93
- in fulminant hepatic failure, 145, 149
- kidney function and, 79-81
- nutritional support in, 79-96
  - consequences of, 82-84, 91-92
  - for at-home care, 92
  - for dialysis patient, 88-90, 92-93
  - for hospitalization, 93
  - goals in, 92
  - in end-stage renal disease, 81-83, 85-87
  - instruction for, 92
  - posttransplantation, 90-92
  - problems in, common, 93-94
- transplantation for, nutritional issues in, 90-92
- Renal insufficiency, after cardiac transplantation, 645-646
- Renal system, in disseminated intravascular coagulation, 401-402
- Rendu-Osler-Weber disease, 445
- Reperfusion injury, coagulation and inflammation in, 421-423
  - definition of, 421
  - pathophysiology of, 422-424
- Respiratory function, treatment outcomes management and, continuum of care in, 744
  - emergency department and, 747-748
- Respiratory insufficiency, after cardiac transplantation, 640
- Respiratory system, senescence of, 737-738
- Resting-energy expenditure (REE), 12-13
- Resuscitation, fluids in, 196
  - pharmacotherapy in, administration routes in, 248-250
  - cardiopulmonary resuscitation and, 250-255
    - for bradyarrhythmias, 257-258
    - for ventricular arrhythmias, 256-257
  - objectives of, 247-248
  - outcomes and, 247-259
  - success of, predictors of, 250
  - vasoactive drugs in, 250-252
- Revascularization, myocardial. *See* Coronary artery bypass grafting (CABG).
- Ribonucleic acid, in enteral nutrition, 26-27
- Salicylates, 289, 291
  - vitamin K deficiency from, 456
- SCD. *See* Sudden cardiac death (SCD).
- Sclerotherapy, endoscopic injection, for esophageal varices, bleeding, 155, 159
- SDC. *See* Serum drug concentration (SDC).
- Seizures. *See also* Status epilepticus.
  - anticonvulsant agents for, 238-239
  - management of, 240
  - pathophysiology of, 237-238
- Sepsis, antithrombin III in, 504
  - in fulminant hepatic failure, 149
  - in pancreatitis, acute, 193-194
- Seroma, postoperative, in cardiomyoplasty, 632
- Serum drug concentration (SDC), elimination and, 230-231
  - interpretation of, 231-232
  - responses to, 227-228
  - samples for, interpretation of, 231-232
  - timing of, 232-234
  - steady state and, 231
  - therapeutic range of, 229
  - tissue concentration and, 227-228
- Shock, cardiogenic, fulminant hepatic failure from, 143

- septic, antitumor necrosis factor for, 338
  - clinical signs of, 345-347
  - colony stimulating factors for, 334-335
  - corticosteroids for, 335
  - hyperdynamic response in, 346
  - hypodynamic phase in, 346-347
  - immunotherapy for, 335-337, 347-350, 354. *See also* Antiendotoxin therapy.
  - incidence of, 345
  - interleukin-1 receptor antagonists for, 338-339
  - management of, conventional, 334, 347
  - mortality from, 333-334, 345
  - opioid antagonists for, 339
  - pathophysiology of, 345-346
- Short gut syndrome, causes of, 103-104
  - small intestine transplantation for, 203-213
- Shunts, for esophageal varices, portacaval, 160
  - splenoportal, distal, 159-160
- Skin, in disseminated intravascular coagulation, 402
- Small intestine, transplantation of, 203-213
  - complications of, 210-211
  - criteria for, 103
  - donor in, 204
  - graft monitoring following, 209-210
  - graft-versus-host disease and, 211-212
  - immunosuppression following, 206-207, 212
  - indications for, 103
  - infection following, 212
  - intensive care following, 207
  - nutrition following, 210
  - outpatient care following, 208
  - patient teaching following, 208-209
  - procedure for, 205-206
  - psychosocial issues following, 212-213
  - recipient of, 204-205
  - rejection of, 211
  - surgical unit care following, 208
- Sodium, in nutritional support, 31-32
- SOLVD (Studies of Left Ventricular Dysfunction),
  - angiotensin-converting enzyme inhibition and, 602-603
- Sonoclot, 468
- SRMD. *See* Stress-related mucosal damage (SRMD).
- Stab wounds, to chest, 691
- Stanozolol, for lipoprotein(a) reduction, 441-442
- Starvation, assessment for, 1-2
  - stress response in, in children, 69-70
- Stasis, deep venous thrombosis and, 489-490
- Status epilepticus, anticonvulsant therapy for, 238-239
  - definition of, 237-238
  - management of, 240-241
- Stomach, trauma to, 133
- Streptase. *See* Streptokinase (Kabikinase; Streptase).
- Streptokinase (Kabikinase; Streptase), 359-360
- Stress-related mucosal damage (SRMD), antacids for, 326-327
  - histamine-2 antagonists for, adverse effects of, 329
  - drug interactions with, 329
  - studies of, 327-329
  - vs. sucralfate, 330
  - mortality from, 325-326
  - pathophysiology of, 325-326
  - prophylaxis of, antacids in, 326-327
    - histamine-2 antagonists in, 327-329
    - pneumonia from, nosocomial, 330
    - sucralfate in, 329-330
  - risk for, 326
- Stress response, assessment of, in hypermetabolism, 100-101
  - in diabetes, during critical illness, 49-50



- metabolic, in diabetic patient, 49-50  
starvation and, in children, 69-70
- Stress ulceration, 163-169. See also *Stress-related mucosal damage (SRMD)*.  
bleeding in, management of, 168-169  
definition of, 163  
diagnosis of, 165-167  
differential, 165  
goals in, 165  
risk factors in, 165  
factors in, aggressive, 164  
epithelial regeneration, 164-165  
mucosal, 164  
mucus secretion, 164  
prostaglandins, endogenous, 165  
histamine-2 antagonists for, 325-331  
mucosa in, defensive mechanisms in, 168  
pH in, control of, 167-168  
monitoring of, 165-167
- Stroke, ischemic, atherosclerotic, 525  
classification of, 525-526  
incidence of, 525  
thrombotic, 525
- Studies of Left Ventricular Dysfunction (SOLVD),  
angiotensin-converting enzyme inhibition in, 602-603
- Succinylcholine (Anectine), 301-302  
in trauma anesthesia, 706-707
- Sucking chest wounds. See *Pneumothorax, communicating*.
- Sucralfate, for stress ulceration, 168
- Sudden cardiac death (SCD), from chronic heart failure, 609-617  
etiology of, 609-611  
autonomic nervous system in, 610-611  
ventricular dysrhythmias in, 609-610  
incidence of, 609-610  
markers or triggers of, atrial fibrillation, 611-612  
heart rate variability, 612-614  
morning hours, 611-612  
syncope, 612  
prevention of, antidysrhythmic devices for, 615  
cardiopulmonary resuscitation training for, 615  
education in, 615  
heart transplantation for, 613, 615  
pharmacologic, 613  
with left ventricular dysfunction, 625
- Syncope, in chronic heart failure, sudden cardiac death from, 612
- Systemic inflammatory response syndrome, assessment of, 425
- Systolic failure, in congestive heart failure, intravenous therapy for, 263-266  
titration to oral, 264-266  
oral agents for, 266-267  
pathology of, 261-262
- Taurine, in enteral nutrition, 27-28
- TEE. See *Transesophageal echocardiography (TEE)*.
- Telangiectasia, hereditary hemorrhagic, 445
- TENS (transcutaneous electrical nerve stimulation), 719
- Therapeutic drug monitoring, common drugs in, 229  
indications for, 229  
recommendations for, 232-233  
steady state in, 231-232  
therapeutic range in, 227-228
- Thoracic trauma, adult respiratory distress syndrome following, 723-734  
anesthesia and, 697-711  
blunt, 673-686  
in elderly, 735-740. See also *Elderly, chest trauma in*.  
outcomes model for, 741-755  
pain management in, 713-722  
penetrating, 687-696
- Thoracic tube, in pleural space injuries, 678-679
- Thrombectomy, for mesenteric ischemia, 174-175
- Thrombin, inhibition of, 397  
by antithrombin III, 499-500  
production of, in clotting cascade, 394-395
- Thrombocytopenia, heparin-associated, 520-521  
in pregnancy, 483-484  
etiology of, 483-484  
management of, 484  
pathophysiology of, 484
- Thromboelastography, 468
- Thromboembolisms. See also *Pulmonary embolism*;  
*Thrombosis, deep venous*.  
diagnosis of, 491-492  
etiology of, 489-490  
antithrombin III deficiency, 502-503  
implantation of ventricular assist devices, 657  
treatment of, 503  
incidence of, 489
- Thrombolysis, agents for, 512. See also *named agent, e.g. Alteplase*.  
adverse effects of, 365  
alteplase, 362, 364-365  
streptokinase, 359-360  
urokinase, 360-363  
bleeding following, 512-513  
interventions for, at vascular site, 513-514  
risk factors for, 516  
cerebral infarction following, 515-516  
contraindications to, 359, 514-515  
cost of, 380  
endogenous, 356  
exogenous, 356-357  
rationale for, 357-358  
indications for, acute myocardial infarction, 511  
studies of, 358-359  
mesenteric ischemia, 174  
occlusive disorders, 359  
pulmonary thrombosis, 494  
hemorrhage following, intracerebral, 515  
intracranial, 514, 516-517  
subarachnoid, 515-516  
neurologic complications of, 514-517
- Thrombophilia, hereditary, 501-503
- Thrombosis, arterial, lipoprotein(a) in, 435-443. See also *Lipoprotein(a)*; *Lipoprotein(s)*.  
assessment of, 425-426  
atherosclerotic, 525  
deep venous, embolization in, 490-491  
etiology of, 489-490  
prevention of, 494  
thrombus formation in, 490  
venography in, contrast, 492  
in disseminated intravascular coagulation, 399-400  
venous, antithrombin III deficiency in, 499-509. See also *Antithrombin III, deficiency of*.
- Thunder Project. See also *Cannulation, arterial*.  
data collection procedure in, 557-558  
objective of, 557  
observations from, 559-560
- Tissue plasminogen activator (TPA). See *Alteplase (recombinant tissue plasminogen activator [r-TPA])*.
- Total artificial heart, 658
- Total lymphocyte count, 10, 12
- Total parenteral nutrition (TPN), diabetes and, 51-52  
drug compatibility with, 35

- Total parenteral nutrition (TPN) (*Continued*)  
 electrolyte salt forms in, 31-32  
 for children, 70  
   devices for, 67  
   formulation of, 72  
 for diabetic patient, administration of, 51  
   components of, 51  
   hyperglycemia from, 51-52  
   insulin and, 53-54  
   nursing considerations and, 55  
 in pancreatitis, 40, 198  
 magnesium in, 33
- Toxicity(ies), neurologic, after bone marrow transplantation, 540
- renal, from aminoglycosides, 373-374  
 from antithrombin III, 504
- Tracheobronchial tree, blunt injuries to, airway management in, 680  
 monitoring of, 680-681  
 tears and rupture, 679-680
- Tranexamic acid, for coagulopathy, postoperative, 469-470
- Transcutaneous electrical nerve stimulation (TENS), for pain, 719
- Transdermal system, for analgesia, 293
- Transesophageal echocardiography (TEE), in thoracic trauma, 675
- Transferrin, serum, 9, 11
- Transfusion, assessment for, 552-553  
 complications from, 408  
 disease transmission via, 551-552  
 indications for, 544  
   of cryoprecipitate, 548-549  
   of factor concentrates, 548, 555  
   of fresh frozen plasma, 547-548, 554  
   of granulocytes, 549-550, 555  
   of platelets, 468-469, 546-547, 555  
   of red blood cells, 545-546  
   of whole blood, 545  
   patient education for, 553  
   personnel coordination in, 553  
   reactions to, allergic, 551  
     endotoxin, 552  
     graft-versus-host disease, 551  
     hemolytic, acute, 550  
       delayed, 551  
     nonhemolytic, febrile, 550-551  
   therapeutic, history of, 543
- Transplantation, bone marrow, 531-542  
 cardiac, 635-648  
   kidney, nutritional issues in, 90-92  
   liver, for esophageal varices, 161  
     for fulminant hepatic failure, 149-150  
     for pancreatobiliary disease, 42-43  
   reperfusion injury following, 424  
   small intestine, 203-213
- Trauma, thoracic, 671-755  
 adult respiratory distress syndrome and, 723-734  
 anesthesia in, 697-711  
 blunt, 673-686  
   in elderly, 735-740  
   outcomes management model for, 741-755  
   pain management in, 713-722  
   penetrating, 687-696
- Trauma outcomes management model, 741-755  
 continuum of care and, 743-747  
   airway parameters and defining characteristics in, 743  
   cardiovascular function in, 745  
   respiratory function in, 744  
   critical care unit guides, 746, 749, 752  
   advantages of, 749-750  
   design factors in, 742-743  
   emergency department guides in, 746-749  
     for cardiovascular function, 749-750  
     for respiratory function, 747-748  
   patient similarities and differences in, 742-743
- Triceps skinfold thickness, 7
- Tube feedings. *See Enteral nutrition.*
- Tumor necrosis factor (TNF), in coagulation and inflammation, 417
- Urokinase (Abbokinase), for acute myocardial infarction, 360  
 for peripheral arterial occlusion, dosage of, 360, 362  
 infusion of, coaxial method in, 360-361  
   pump set-up for, 360, 363  
 reconstitution of, 362
- Valium. *See Diazepam (Valium).*
- Valproate, for seizures, 239
- Valproic acid, for seizures, 239
- Vasoconstriction, in hemostasis, 453, 459
- Vasodilator(s), direct-acting, arterial, 578  
   calcium channel blockers, 579-580  
   non-calcium channel-dependent, 578-589  
   balanced venous/arterial, 580  
   combination therapy, 580-581  
   effects of, 576-577  
   neurohumoral system and, 576-577  
   venodilators, 578  
   for congestive heart failure, acute, 263  
   for chronic heart failure, 578-581
- Vasopressin, for esophageal varices, bleeding, 155, 159
- VATS. *See Video-assisted thoracic surgery (VATS).*
- Vecuronium, 303
- Vena caval interruption, for pulmonary thrombosis, 494-495
- Ventilation, in flail chest injury, 674  
 in pulmonary injury, 675  
   mechanical, aerosol therapy with, 271-280  
   neuromuscular blocking agents in, 297, 299
- Ventricular arrhythmias, pharmacotherapy for, in resuscitation, 256-257
- Ventricular assist device(s) (VADs), 649-659  
 characteristics of, 649  
 indications for, 650  
 intermediate, 653-656  
   comparison of, 655  
   HeartMate 1000 LVAD, 655-656  
   Novacor, 653-655  
   permanent, total artificial heart, 658  
   post-implant considerations, 656-658  
   quality of life with, 666  
   short-term, centrifugal pumps, 650-651  
     extracorporeal membrane oxygenation system, 651-653  
     pulsatile pump, 653-654
- Ventricular dysrhythmias, sudden cardiac death from, 609-610
- Verapamil, in congestive heart failure, acute, 268  
 in pediatric patient, 373
- Versed. *See Midazolam (Versed).*
- Very low-density lipoproteins (VLDLs), 436-437

- Veterans Administration Cooperative studies, of  
  combination therapies, for chronic heart failure,  
  580-581
- Video-assisted thoracic surgery (VATS), in emergency  
  room, 692
- Visual analogue scales, for pain, 716
- Vitamin K, deficiency of, coagulopathies from, 455-456  
  in enteral formulas, 4-5
- VLDLs. See *Very low-density lipoproteins (VLDLs)*.
- von Willebrand disease, coagulopathies in, 446-447  
  treatment of, cryoprecipitate in, 549
- von Willebrand syndrome, in pregnancy, 484-485
- Warfarin, bleeding with, 517-518  
  evaluation of, 519  
  patient education in, 518-519  
  risk for, 517-519  
  characteristics of, 517  
  drug interactions with, 518  
  uses of, 517